These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 24903436)

  • 21. Drug Level-based Anti-Tumor Necrosis Factor Therapy: Ready for Prime Time?
    Ben-Horin S
    Gastroenterology; 2015 Jun; 148(7):1268-71. PubMed ID: 25921372
    [No Abstract]   [Full Text] [Related]  

  • 22. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M; Vermeire S; Steen KV; Joossens S; Claessens G; Vlietinck R; Rutgeerts P
    Aliment Pharmacol Ther; 2004 Aug; 20(3):303-10. PubMed ID: 15274667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo single-photon emission computed tomography imaging of apoptosis in Crohn's disease and anti-tumour necrosis factor therapy.
    Watson AJ
    Gut; 2007 Apr; 56(4):461-3. PubMed ID: 17369380
    [No Abstract]   [Full Text] [Related]  

  • 25. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
    Singh N; Rosenthal CJ; Melmed GY; Mirocha J; Farrior S; Callejas S; Tripuraneni B; Rabizadeh S; Dubinsky MC
    Inflamm Bowel Dis; 2014 Oct; 20(10):1708-13. PubMed ID: 25153505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease.
    Dideberg V; Théâtre E; Farnir F; Vermeire S; Rutgeerts P; De Vos M; Belaiche J; Franchimont D; Van Gossum A; Louis E; Bours V
    Pharmacogenet Genomics; 2006 Oct; 16(10):727-34. PubMed ID: 17001292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease.
    Hibi T; Sakuraba A; Watanabe M; Motoya S; Ito H; Motegi K; Kinouchi Y; Takazoe M; Suzuki Y; Matsumoto T; Kawakami K; Matsumoto T; Hirata I; Tanaka S; Ashida T; Matsui T
    Inflamm Bowel Dis; 2012 Aug; 18(8):1480-7. PubMed ID: 21987418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Infliximab--practical guidelines for the treatment of Crohn's disease].
    Bauerfeind P; Beglinger C; Beltinger J; Braegger C; Eigenmann F; Fried M; Guyot J; Hürlimann R; Michetti P; Seibold F; Straumann A
    Rev Med Suisse; 2006 Jul; 2(74):1807-15. PubMed ID: 16927560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect.
    Raffáč Š; Gombošová L; Gabzdilová J; Novotná L; Šajtyová K; Pekárová T; Kopolovets I; Tóth Š
    Neuro Endocrinol Lett; 2017 Nov; 38(Suppl1):5-9. PubMed ID: 29200248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Indications and results of infliximab in Crohn's disease].
    Karoui S; Boubaker J; Filali A
    Tunis Med; 2004 Dec; 82(12):1057-63. PubMed ID: 15822505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Adalimumab treatment in infliximab-resistant pediatric patient with Crohn's disease].
    Veres G; Putz R; Szabó D; Molnár K; Bodánszky H; Dezsofi A; Arató A
    Orv Hetil; 2009 Oct; 150(40):1858-60. PubMed ID: 19789146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic amyloidosis with Crohn's disease treated with infliximab.
    Park YK; Han DS; Eun CS
    Inflamm Bowel Dis; 2008 Mar; 14(3):431-2. PubMed ID: 17932971
    [No Abstract]   [Full Text] [Related]  

  • 37. Infliximab dose intensification by shortening infusion intervals.
    Magro F; Bastos R; Marques M; Costa Santos C
    Inflamm Bowel Dis; 2008 Mar; 14(3):432-4. PubMed ID: 18022873
    [No Abstract]   [Full Text] [Related]  

  • 38. [A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy].
    Park SH; Jeen YT; Chun HR; Kim DI; Baeck CW; Kim YS; Chun HJ; Lee HS; Um SH; Choi JH; Kim CD; Ryu HS; Hyun JH
    Korean J Gastroenterol; 2005 Oct; 46(4):297-301. PubMed ID: 16247274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pericarditis as a complication of infliximab therapy in Crohn's disease.
    Burke JP; Kelleher B; Ramadan S; Quinlan M; Sugrue D; O'Donovan MA
    Inflamm Bowel Dis; 2008 Mar; 14(3):428-9. PubMed ID: 17924565
    [No Abstract]   [Full Text] [Related]  

  • 40. Severe agranulocytosis following first infliximab infusion in Crohn's disease.
    Rosales-Zábal JM; Fernández-Pérez F; Albandea-Moreno C; Vera-Rivero FM; Navarro-Jarabo JM
    Inflamm Bowel Dis; 2011 Nov; 17(11):E147-8. PubMed ID: 21830280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.